Brokerages Set Phreesia, Inc. (NYSE:PHR) Target Price at $31.15

Phreesia, Inc. (NYSE:PHR) has earned a consensus recommendation of “Buy” from the thirteen research firms that are presently covering the company, MarketBeat reports. Thirteen analysts have rated the stock with a buy rating. The average 12 month price target among analysts that have issued a report on the stock in the last year is $31.23.

Several brokerages have recently weighed in on PHR. Truist Financial increased their target price on shares of Phreesia from $31.00 to $34.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. JMP Securities reiterated a “market outperform” rating and set a $30.00 target price on shares of Phreesia in a research note on Tuesday, December 10th. Canaccord Genuity Group raised their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a “buy” rating in a research report on Thursday. Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Phreesia in a research report on Thursday. Finally, Citigroup raised their price objective on shares of Phreesia from $31.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, January 10th.

Insider Buying and Selling at Phreesia

In other news, COO Evan Roberts sold 3,519 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $30.06, for a total transaction of $105,781.14. Following the completion of the transaction, the chief operating officer now directly owns 741,197 shares of the company’s stock, valued at $22,280,381.82. This trade represents a 0.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel Allison C. Hoffman sold 3,495 shares of the firm’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $24.88, for a total transaction of $86,955.60. Following the transaction, the general counsel now directly owns 116,296 shares of the company’s stock, valued at approximately $2,893,444.48. This trade represents a 2.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 163,322 shares of company stock valued at $4,631,915. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Probity Advisors Inc. purchased a new position in shares of Phreesia during the 4th quarter worth approximately $304,000. PharVision Advisers LLC purchased a new position in shares of Phreesia during the 4th quarter worth approximately $302,000. Two Sigma Advisers LP purchased a new position in shares of Phreesia during the 4th quarter worth approximately $302,000. Silvercrest Asset Management Group LLC increased its stake in shares of Phreesia by 31.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 394,352 shares of the company’s stock worth $9,922,000 after purchasing an additional 93,349 shares in the last quarter. Finally, ProShare Advisors LLC increased its stake in shares of Phreesia by 49.0% during the 4th quarter. ProShare Advisors LLC now owns 15,585 shares of the company’s stock worth $392,000 after purchasing an additional 5,127 shares in the last quarter. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia Stock Performance

NYSE PHR opened at $25.49 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. Phreesia has a 1 year low of $17.07 and a 1 year high of $30.53. The company has a market capitalization of $1.48 billion, a PE ratio of -17.34 and a beta of 1.03. The company has a fifty day moving average of $27.32 and a two-hundred day moving average of $24.00.

Phreesia (NYSE:PHR) last announced its earnings results on Monday, December 9th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.04. Phreesia had a negative net margin of 20.43% and a negative return on equity of 32.78%. The business had revenue of $106.80 million during the quarter, compared to the consensus estimate of $106.33 million. During the same quarter in the prior year, the firm earned ($0.58) earnings per share. The business’s quarterly revenue was up 16.6% compared to the same quarter last year. As a group, analysts expect that Phreesia will post -1.1 earnings per share for the current year.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.